CME Group, Inc.

As of June 30, 2025, CME Group, Inc. is fairly valued with a P/E ratio of 27, an EV to EBITDA of 22.04, and a Price to Book Value of 3.66, showing competitive positioning despite recent stock performance lagging behind the S&P 500 over longer periods.

As of June 27, 2025, CME Group, Inc. shows a bullish trend supported by strong monthly indicators, although short-term signals suggest some caution.

As of June 4, 2025, CME Group, Inc. is fairly valued with a P/E ratio of 27 and an EV to EBITDA of 22.04, outperforming the S&P 500 with a 1-year return of 40.20%, while its valuation is competitive compared to peers like Goldman Sachs and Morgan Stanley.

As of June 20, 2025, CME Group, Inc. shows a bullish trend supported by monthly indicators, though mixed signals from weekly indicators suggest some short-term weakness.

As of March 2022, the management team of CME Group, Inc. includes Executive Chairman and CEO Terrence Duffy, Vice Chairman Charles Carey, Lead Independent Director Daniel Glickman, and several Independent Directors: Michael Spencer, Timothy Bitsberger, Dennis Chookaszian, and Elizabeth Cook. This team is responsible for the company's strategic direction and governance.

CME Group, Inc. operates in the capital markets, offering a variety of futures and options products across all asset classes. As of March 2025, it reported net sales of $1.642 billion and a net profit of $950 million, with a market cap of approximately $97.19 billion.

As of Jun 18, CME Group, Inc. has a market capitalization of $97.19 billion, with net sales of $6.28 billion and a net profit of $3.63 billion over the last four quarters. The company also reported total assets of $137.59 billion and shareholder's funds of $26.49 billion as of Dec 24.